Monday, October 28, 2024

Paclitaxel Containing Devices in Femoropopliteal Arterial Disease: The Trees and the Forest

An Up To Date Meta-Analysis on Paclitaxel Containing Devices in Femoropopliteal Arterial Disease, And A Commentary On The Entirety of the Data to Date.

Clinical question

Is paclitaxel safe when used in drug eluting stents and drug coated balloons for revascularization of the femoropopliteal artery?

Take away point

Paclitaxel containing devices are safe and effective devices, especially in their current usage and at their current generation. Previous versions of the devices may have conveyed some mortality risk, but it’s important to understand both the meta-analyses and the individual studies that comprise the data reporting, and how clinical practice is nuanced and so does the literature..

Reference

Katsanos, K. (2024). Paclitaxel meta-analyses in the lower limbs: Missing the trees for the forest. Journal of Vascular and Interventional Radiology.
Click here to access article

Briody, H., Kearns, C. A., & Lee, M. J. (2024). Mortality, safety and efficacy of paclitaxel-containing balloons and stents in the femoropopliteal artery: systematic review and meta-analysis of randomized controlled trials since 2018. Journal of Vascular and Interventional Radiology. 
Click here to access article

Study design

Meta-analysis, commentary/perspective

Setting

Meta-analysis was performed at Beaumont Hospital, Dublin Ireland and the Royal College of Surgeons in Ireland.
Commentary is from University Hospital Patras, School of Medicine, Rio, Greece.

Figure



Summary


In revascularization efforts for peripheral arterial disease, paclitaxel has proven to be an excellent anti-restenotic agent in the femoropopliteal artery when used in drug coated balloons and drug eluting stents in multiple randomized controlled trials. While effective, its safety profile was called into question in a 2018 meta-analysis. The meta-analysis, published by Katsanos et al, found statistically significant increases in all-cause death in patients with paclitaxel coated devices, and urged further investigations. In 2023, a patient level, industry funded meta-analysis concluded there was no excess mortality. Based on this study, the FDA published their official statement that there is no discernible excess of mortality.

The current meta-analysis was performed to provide an independent analysis of safety and effectiveness outcomes, including but not limited to mortality. The literature search was performed from 2018 (a choice made so this study would act as an update of the aforementioned Katsanos study) and included 19 randomized controlled trials for a total of 4,284 participants. When selecting studies, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was utilized (see figure). Effectiveness outcomes were primary patency which was analyzed using risk ratios via inverse variance, random-effects model. Safety outcomes were all cause mortality, target limb amputation, target lesion revascularization, clinically driven target lesion revascularization, and thrombosis. These were also analyzed using risk ratios via inverse variance, random effects model, as well as heterogeneity assessment via visual inspection of forest plots, chi squared test and I^2 statistic.

The results found no evidence for all-cause mortality in paclitaxel containing devices in the femoropopliteal region from 12 to 60 months, nor did they find any other safety concerns. The study redemonstrated the effectiveness of paclitaxel devices in maintaining primary patency with a pooled risk ratio of 1.55. Taken together, this meta-analysis concluded that paclitaxel containing devices work, and are safe to use. They compare this study directly to the Katsanos study due to its similar methodology and design, however they offer no suggestions as to the source of the different findings.

In response to the multiple meta-analyses looking at the use of paclitaxel containing devices in the femoropopliteal arteries with no evidence of increased all-cause mortality, Dr. Konstantinos Katsonas provided a companion commentary. In the piece, he presents 27 studies from 2008-2021 which show an increase in all-cause mortality in the paclitaxel containing device arm, arguing that the recent studies demonstrate dilution of the mortality signal, but do not eradicate it completely. He presents a meta-regression of long-term risk ratio of all cause death against publication year and shows that the observed mortality risk decreases with publication year, which would seem to suggest earlier generation devices or clinical practices may be the cause for the mortality signal. He further subgroups the studies by paclitaxel dosage and shows that the relative mortality risks may be different among the different devices with variable paclitaxel dosing. He concludes that the reader must not miss the trees for the forest, meaning that the individual studies may have points of interest that become diluted in meta-analysis.

Commentary


The academic discussion around paclitaxel can make it difficult for providers to know if these devices are safe or not. This most recent meta-analysis is an excellent consolidation of the most recent literature on paclitaxel containing devices in femoropopliteal artery treatment. The results add to the body of evidence that these paclitaxel devices are safe and effective tools in peripheral arterial disease, especially at their current generations. Providers can use these devices and expect good outcomes for their patients without an increased mortality risk.

That being said, Dr. Katsonas does raise interesting questions. The 2018 Katsonas et al meta-analysis did show a significant increase in all-cause mortality. In his commentary, this effect appeared again when looking at all studies from 2008-2021. While there were shortcomings in the Katsonas paper, the fact remains that a mortality signal was present and hasn’t been fully accounted for. The fact that it seems to disappear when looking at studies from only 2018 onward could be indicative of the root cause. Moreover, the more recent studies did not subgroup based on device or paclitaxel dosing. The data he presents on the decrease of all-cause mortality risk over the years, as well as the trend of lower risk ratios with lower paclitaxel dosing, are suggestive that the mortality signal may be device-, device-generation, and/or paclitaxel dosage-dependent. Of course, this is only speculation based on available data, but could make excellent areas of inquiry should the question of safety in paclitaxel containing devices remain.

Dr. Katsonas’ final point is to not miss the “trees” (individual studies) for the “forest” (meta-analysis), as individual studies can yield insights that may be diluted in meta-analyses. However, he doesn’t really support this in his commentary, as most of his points are made by using grouping statistics based on multiple studies. Regardless, it is an important point to keep in mind when reading meta-analyses. Procedural practice and published literature are nuanced, and evidence-based medicine should be supported by both high-level meta-analyses as well as individual studies that befit the patient population and institutional experience.

Post Author
Sean Rogers, MD
Interventional Radiology Fellow, PGY-6
University of Massachusetts Chan Medical School

Wednesday, September 25, 2024

Radiofrequency Lung Ablation in ILD

Radiofrequency Ablation in Patients with Interstitial Lung Disease and Lung Neoplasm: A Retrospective Multicenter Study


Clinical Question

Is percutaneous radiofrequency ablation safe and effective against lung neoplasms in patients with interstitial lung diseases?

Take Away Point

Radiofrequency ablation is a feasible technique in combating lung neoplasms in patients with interstitial lung diseases but there are risks of post-procedural acute exacerbations which has a relatively high mortality rate of 45%.

Reference

Yamamoto A, Hiraki T, Ikeda O, et al. Radiofrequency ablation in patients with interstitial lung disease and lung neoplasm: A retrospective multicenter study. Journal of Vascular and Interventional Radiology. 2024;35(9):1305-1312. doi:10.1016/j.jvir.2024.06.010

Click here for abstract

Study Design

Retrospective, observation, cohort study

Funding Source

No reported funding

Setting

Academic, Osaka Metropolitan University, et al, Japan

Figure



Summary


Interstitial lung diseases are generally irreversible with poor prognosis. There is no optimal therapeutic approach for concomitant lung neoplasms, which has a frequency of 10-20%. Radiofrequency ablation is a safe and effective treatment strategy for inoperable primary and metastatic lung lesions. The authors of this paper decided to investigate the safety and efficacy of radiofrequency ablation in combating lung tumors in patients with interstitial lung diseases due to lack of pertinent data.

The authors performed a multi-institutional retrospective observational study acquiring data of all the patients diagnosed with lung neoplasm and interstitial lung disease from April 2002 and October 2017 who underwent radiofrequency ablation, with their respective images reassessed by radiologic review. After central radiologic review excluded patients who did not have interstitial lung disease, 49 patients remained in the sample, 43 men and 6 women. Within the 49 patients, there were 64 tumors—34 of which were primary neoplasms and 30 of which were metastatic—with 66 treatment sessions.

Technical success was defined as completion of the radiofrequency procedure. Adverse events were based on the parameters set by the modified definitions of Society of Interventional Radiology, including unexpected increase in the level of care, prolonged hospital stay, or death. The following variables were also included in the study: local tumor progression, overall survival, and acute exacerbation of interstitial lung disease after ablation. Acute exacerbation diagnosis was based on radiologic or clinical diagnosis.

Technical success rate was 100%. While no adverse events occurred during the procedure, multiple events occurred after the procedure, the most frequent being pneumothorax in 53% (35/66 treatment sessions). The rest of the listed adverse events are summarized in Table 3 provided in this article. Acute exacerbations occurred in 8% of the study (5 patients). Among these 5 patients, 3 passed away despite initiation of steroid treatment (60%). The events of acute exacerbations did not differ significantly between patients with UIP (8%) and those without UIP (7%). Additionally, onset of acute exacerbation always occurred at least 8 days after radiofrequency ablation. Univariate analysis determined that pleural effusion and fever were statistically significant risk factors for development of acute exacerbations. Local tumor progression rate was 43% at one year. The overall survival rate at one, three, and five-years were 83%, 62%, and 36%, respectively.

While the results have demonstrated that radiofrequency ablation can be feasible for treating lung neoplasm in patients with interstitial lung disease, the results do not provide consensus recommendations. With regards to procedural safety, prior literature has demonstrated that ablation for lung neoplasms is safe, with mortality rate <1%, which is significantly lower than the mortality rate in patients with interstitial lung disease reported in this series, at 5% per session. The rate of 8% for acute exacerbation and an associated mortality rate of 45% may seem alarming at first. However, the rate of acute exacerbation after surgery was similar to that of ablation at 9.3%, with a similar mortality rate at 43.9%. Similarly, acute exacerbation can occur after thoracic radiotherapy and pharmacotherapy. After all, patients with idiopathic pulmonary fibrosis and non-idiopathic pulmonary fibrosis interstitial lung diseases develop acute exacerbations at a rate of 10-20%, and 3-5%, respectively annually during the natural course. The safety profile of radiofrequency ablation for lung neoplasm should be considered within this specific patient population and not taken out-of-context.

With regards to the local tumor progression rates, various factors may have contributed, both from the operator and from the lesion pathology. The operator may not have had sufficient margin, partly due to the intention to minimize adverse events. Additionally, patients with severe emphysema or UIP may present challenges to the accurate identification of the overall tumor burden, complicating the assessment of local tumor progression. Furthermore, fibrotic changes such as those seen in usual interstitial pneumonia may reduce the ablation’s electrical and thermal conductivity, limiting the tumoricidal effect of radiofrequency ablation.

This study had several limitations apart from its retrospective design. Firstly, interstitial lung disease diagnosis was not based on pathological findings. Secondly, central reading to evaluate interstitial lung disease was only applied to those that were already diagnosed as such, making the study prone to additional selection bias. Multivariate analysis to identify independent risk factors for acute exacerbations could improve the quality of the study. Sub-analyses, which may require a larger study, focusing on patients with primary neoplasms, and patients with metastatic lesions, separately, will provide further clinically relevant information and guidance.

Commentary


Despite several limitations, this article assessing radiofrequency ablation for the treatment of lung neoplasms in patients with concomitant pulmonary pathologies like interstitial lung disease is of significant clinical relevance. Risk factors that predispose patients to interstitial lung disease such as smoking are very prevalent, especially in certain countries like Japan. Referring and treatment physicians of patients with interstitial lung disease need information specific to the patient population. Clinical guidelines and treatment algorithms also require such information for development and refinement. In conclusion, radiofrequency ablation appears feasible in patients with interstitial lung disease with a risk of post-procedural acute exacerbation grossly similar to other treatment modalities.

Post author
Naeem Patel, DO
Radiology Resident, PGY4
Department of Radiology, Interventional Radiology Division
Hartford Hospital, Hartford, CT
@Naeemp7Patel

Tuesday, August 27, 2024

Systemic Review of Persistent Sciatic Artery Management

Safety and Effectiveness of Endovascular Treatment of Complications Associated with Persistent Sciatic Artery: A Qualitative Systematic Review


Clinical question

Is endovascular therapy with stent grafts (SGs) a safe and effective approach to treat complications associated with persistent sciatic artery (PSA)?

Take away point

The current review demonstrated good technical and clinical success rates and a low risk of adverse events with endovascular stent graft management of persistent sciatic artery.

Reference

Koike, Y., Motohashi, K., & Kato, S. (2024). Safety and Effectiveness of Endovascular Treatment of Complications Associated with Persistent Sciatic Artery: A Qualitative Systematic Review. Journal of Vascular and Interventional Radiology.

Click here for abstract

Study design

Systemic review, qualitative

Funding Source

None

Setting

Academic

Figure




Summary


Persistent sciatic artery (PSA) is a rare vascular anomaly occurring in 0.025%–0.040% of the population, where the sciatic artery fails to regress during fetal development and continues to supply the lower limb. This anomaly often results in symptoms, with 80% of patients being symptomatic and 48% developing buttock aneurysms due to repetitive trauma and compression from its anatomical position. These aneurysms can lead to complications such as thrombotic occlusion, distal embolization, and even amputation. The primary treatment goals for symptomatic PSA are to prevent distal embolization and aneurysm rupture, typically through bypass surgery combined with embolization. Recently, stent graft (SG) placement has gained attention as an alternative treatment, although concerns about SG durability, potential fracture, and occlusion remain due to the repetitive trauma in the PSA's location. This systematic review aims to assess the safety and effectiveness of endovascular SG placement for treating PSA complications.

This systematic review, registered with the University Medical Information Network, analyzed existing literature on endovascular treatment of persistent sciatic artery (PSA) complications using stent graft (SG) placement. Following PRISMA guidelines, the study included patients with PSA complications such as aneurysms, rupture, or thrombosis, and excluded those without SG placement or without complications at risk of rupture. The literature search, conducted across multiple databases, identified eligible studies based on a predefined PICOS framework. Two authors independently screened and extracted data, resolving discrepancies by consensus. Outcomes assessed included technical and clinical success, patency, SG-related adverse events, reinterventions, amputations, and mortality. Statistical analyses, including Kaplan-Meier curves and Cox regression, were performed to evaluate the associations between SG characteristics and outcomes, with significance set at a p-value of ≤0.05.

The systematic review included 40 records of patients who underwent endovascular treatment with stent grafts (SGs) for persistent sciatic artery (PSA) complications. The study analyzed 31 case reports, 2 case series, and 7 conference proceedings, with a total of 40 patients (median age 67) treated across 41 limbs. Most patients presented with lower limb ischemia or aneurysm. The technical success rate was 100%, but 9.8% of limbs experienced intervention-specific adverse events, including intraprocedural dissection and thrombotic complications. The study found primary and secondary patency rates of 81.5% and 94.5% at 1 year, respectively, with SG occlusions mainly occurring within 2 years. The clinical success rate remained high at 95.7% over two years. SG fracture was rare, and no endoleaks or infections were reported. Univariate analysis showed no significant association between SG characteristics and primary patency rates.

The discussion highlights that endovascular treatment using stent grafts (SGs) for persistent sciatic artery (PSA) complications is effective, showing high technical and clinical success rates with a low risk of adverse events (AEs). The midterm patency and durability of SGs were found to be acceptable, although factors influencing patency remain unclear. The review supports SG placement as a preferable first-line therapy, especially for PSA aneurysms without occlusion, and suggests that endovascular approaches are increasingly favored due to their minimally invasive nature. The discussion also compares the findings with previous reviews and studies, noting similar success rates but emphasizing the need for more consistent follow-up and reporting to better understand long-term outcomes and the potential impact of anatomical factors on patency. The authors recommend SGs as a first-line treatment while acknowledging the limitations of the current data, including potential selection bias and inconsistencies in study methodologies.